Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice

Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering

Volumn 46, Issue 2, 2011, Pages 97-108

  Mollenhauer, Meagan A M ^a   Bradshaw, Sarah G ^a   Fair, Patricia A ^b   McGuinn, W David ^c   Peden Adams, Margie M ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CENTER FOR COASTAL ENVIRONMENTAL HEALTH AND BIOMOLECULAR RESEARCH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF NEVADA   (United States)

Author keywords

cytokines; IL 6; immune; inflammation; macrophages.; PFOS; TNF

Indexed keywords

CYTOKINES; IL-6; IMMUNE; INFLAMMATION; PFOS; TNF;

BODY FLUIDS; PATHOLOGY;

MACROPHAGES;

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PERFLUOROOCTANESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; INFLAMMATION; MOUSE; NONHUMAN; PERITONEAL FLUID; PERITONEUM LAVAGE; PERITONEUM MACROPHAGE; SPLEEN CELL; SPLEEN WEIGHT;

ALKANESULFONIC ACIDS; ANIMALS; ASCITIC FLUID; BIOLOGICAL MARKERS; BODY WEIGHT; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED STRAINS; ORGAN SIZE; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 78650444079     PISSN: 10934529     EISSN: 15324117     Source Type: Journal    
DOI: 10.1080/10934529.2011.532418     Document Type: Article

References (70)

1. Giesy, J.P.; Kannan, K. Perfluorochemical surfactants in the environment. Environ. Sci. Technol. 2002, 36(7), 146A-152A.
2. Hu, W.; Jones, P.D.; Celius, T.; Giesy, J.P. Identification of genes responsive to PFOS using gene expression profiling. Environ. Toxicol. Pharmacol. 2005, 19(1), 57-70.
3. Giesy, J.P.; Kannan, K. Global distribution of perfluorooctane sul-fonate in wildlife. Environ. Sci. Technol. 2001, 35(7), 1339-1342.
4. Hekster, F.M.; Laane, R.W; de Voogt, P. Environmental and toxic-ity effects of perfluoroalkylated substances. Rev. Environ. Contam. Toxicol. 2003, 179, 99-121.
5. Houde, M.; Bujas, T.A.; Small, J.; Wells, R.S.; Fair, P.A.; Bossart, G.D.; Solomon, K.R.; Muir, D.C. Biomagnification of perfluo-roalkyl compounds in the bottlenose dolphin (Tursiops truncatus) food web. Environ. Sci. Technol. 2006, 40 (13), 4138-4144.
6. Organization for Economic Co-operation and Development (OECD). Hazard assessment of perfluorooctane sulfonate (PFOS) and its salts. ENV/JM/RD. 2002, (Final).
7. Andersen, M.E.; Butenhoff, J.L.; Chang, S.C.; Farrar, D.G.; Kennedy, G.L., Jr.; Lau, C.; Olsen, G.W.; Seed, J.; Wallace, K.B. Perfluoroalkyl Acids and Related Chemistries-Toxicokinetics and Modes of Action. Toxicol. Sci. 2008, 102(1), 3-14.
8. Jensen, A.A.; Leffers, H. Emerging endocrine disrupters: perfluo-roalkylated substances. Int. J. Androl. 2008, 31(2), 161-169.
9. Lau, C.; Butenhoff, J.L.; Rogers, J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 2004, 198 (2), 231-241.
10. Peden-Adams, M.M.; Keller, J.M.; EuDaly, J.G.; Berger, J.; Gilke-son, G.S.; Keil, D.E. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 2008, 104 (1), 144-154.
11. Hu, W.; Jones, P.D.; DeCoen, W.; King, L.; Fraker, P.; Newsted, J.; Giesy, J.P. Alterations in cell membrane properties caused by perfluorinated compounds. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2003, 135 (1), 77-88.
12. Hu, W.; Jones, P.D.; Upham, B.L.; Trosko, J.E.; Lau, C.; Giesy, J.P. Inhibition of gap junctional intercellular communication by perfluorinated compounds in rat liver and dolphin kidney epithelial cell lines in vitro and Sprague-Dawley rats in vivo. Toxicol. Sci. 2002, 68 (2), 429-436.
13. Guruge, K.S.; Yeung, L.W.; Yamanaka, N.; Miyazaki, S.; Lam, P.K.; Giesy, J.P.; Jones, P.D.; Yamashita, N. Gene expression profiles in rat liver treated with perfluorooctanoic acid (PFOA). Toxicol. Sci. 2006, 89 (1), 93-107.
14. Auer, C., Email to OECD. Subject: Phase out of PFOS. Available on USEPA Public Docket AR-226. 2000, No. 226-0629.
15. Kennedy, G.L.; Jr., Butenhoff, J.L.; Olsen, G.W.; O'Connor, J.C.; Seacat, A.M.; Perkins, R.G.; Biegel, L.B.; Murphy, S.R.; Farrar, D.G. The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 2004, 34 (4), 351-384.
16. Shipley, J.M.; Hurst, C.H.; Tanaka, S.S.; DeRoos, F.L.; Butenhoff, J.L.; Seacat, A.M.; Waxman, D.J. Trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicol. Sci. 2004, 80(1), 151-160.
17. Taylor, B.K.; Dadia, N.; Yang, C.B.; Krishnan, S.; Badr, M. Perox-isome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation. 2002, 26 (3), 121-127.
18. Taylor, B.K.; Kriedt, C.; Nagalingam, S.; Dadia, N.; Badr, M. Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm. Res. 2005, 54(6), 235-242.
19. Vanden Heuvel, J.P.; Thompson, J.T.; Frame, S.R.; Gillies, P.J. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Tox-icol. Sci. 2006, 92(2), 476-489.
20. Takacs, M.L.; Abbott, B.D. Activation of mouse and human perox-isome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 2007, 95(1), 108-117.
21. Chinetti, G.; Fruchart, J.C.; Staels, B. Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 2000, 49(10), 497-505.
22. Daynes, R.A.; Jones, D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002, 2(10), 748-759.
23. Gelman, L.; Fruchart, J.C.; Auwerx, J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci. 1999, 55(6-7), 932-943.
24. Hwang, D. Fatty acids and immune responses-a new perspective in searching for clues to mechanism. Annu. Rev. Nutr. 2000, 20, 431-456.
25. Dewitt, J.C.; Copeland, C.B.; Luebke, R.W. Immune function in intact and PPARα knockout mice exposed to PFOA. Toxicologist (Supplement to Toxicol. Sci.) 2008, 102(S-1), 174.
26. Dewitt, J.C.; Copeland, C.B.; Strynar, M.J.; Luebke, R.W. Perflu-orooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ Health. Perspect. 2008, 116(5), 644-650.
27. Dewitt, J.C.; Shnyra, A.; Badr, M.Z.; Loveless, S.E.; Hoban, D.; Frame, S.R.; Cunard, R.; Anderson, S.E.; Meade, B.J.; Peden-Adams, M.M.; Luebke, R.W.; Luster, M.I. Immunotoxicity of per-fluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit. Rev. Toxicol. 2008, 39(1), 76-94.
28. Fair, P.A.; Driscoll, E.; Mollenhauer, M.A.M.; Bradshaw, S.; Yun, S.; Kannan, K.; Keil, D.E.; Bossart, G.D.; Peden-Adams. M.M. Effects of environmentally relevant levels of perfluorooctane sulfonate (PFOS) on clinical parameters and immunological functions. Submitted.
29. Fairley, K.J.; Purdy, R.; Kearns, S.; Anderson, S.E.; Meade, B.J. Exposure to the Immunosuppresant, perfluorooctanoic acid, enhances the murine IgE and airway hyperreactivity response to ovalbumin. Toxicol. Sci. 2007, 97(2), 375-383.
30. Keil, D.E.; Mehlman, T.; Butterworth, L.; Peden-Adams, M.M. Gestational exposure to perfluorooctane sulfonate (PFOS) suppresses immune function in B6C3F1 mice. Toxicol. Sci. 2008, 103(1), 77-85.
31. Loveless, S.E.; Hoban, D.; Sykes, G.; Frame, S.R.; Everds, N.E. Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate. Toxicol. Sci. 2008, 105(1), 86-96.
32. Nelson, D.L.; Frazier, D.E.; Jr., Ericson, J.E.; Tarr, M.J.; Mathes, L.E. The effects of perfluorodecanoic acid (PFDA) on humoral, cellular, and innate immunity in Fischer 344 rats. Immunopharmacol. Immunotoxicol. 1992, 14(4), 925-938.
33. Peden-Adams, M.M.; EuDaly, J.G.; Dabra, S.; EuDaly, A.; Heese-mann, L.; Smythe, J.; Keil, D.E. Suppression of humoral immunity following exposure to the perfluorinated insecticide sulfuramid. J. Toxicol. Environ. Health Pt. A 2007. 70(13), 1130-1141.
34. Yang, Q.; Abedi-Valugerdi, M.; Xie, Y.; Zhao, X.Y.; Moller, G.; Nelson, B.D.; DePierre, J.W. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2002, 2(2-3), 389-397.
35. Yang, Q.; Xie, Y.; Alexson, S.E.; Nelson, B.D.; DePierre, J.W. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 2002, 63(10), 1893-1900.
36. Yang, Q.; Y. Xie; Depierre, J.W. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol. 2000, 122(2), 219-226.
37. Yang, Q.; Xie, Y.; Eriksson, A.M.; Nelson, B.D.; DePierre, J.W. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluorooctanoic acid in mice. Biochem. Pharmacol. 2001, 62(8), 1133-1140.
38. Hoff, P.T.; Van Dongen, W.; Esmans, E.L.; Blust, R.; De Coen, W.M. Evaluation of the toxicological effects of perfluorooctane sulfonic acid in the common carp (Cyprinus carpio). Aquat. Toxicol. 2003, 62(4), 349-359.
39. El Alwani, M.; Wu, B.X.; Obeid, L.M.; Hannun, Y.A. Bioactive sph-ingolipids in the modulation of the inflammatory response. Pharmacol. Ther. 2006, 112(1), 171-183.
40. Peden-Adams, M.M.; Romano, T.A.; Rice, C.D.; EuDaly, J.; Hes-semann, L.; Muir, D.C.; Houde, M.; Bossart, G.D.; Fair, P.A. Immune function and clinical blood parameters correlate with perflu-orinated hydrocarbon concentrations in bottlenose dolphins. Abstract book, Society of Environmental Toxicology and Chemistry (SETAC) North America 25th Annual Meeting. Portland, OR, Nov 14-18, 2004.
41. Peden-Adams, M.M.; Keil, D.E.; Romano, T.; Mollenhauer, M.A.M.; Fort, D.J.; Guiney, P.D.; Houde, M.; Kannan, K.; Muir, D.C.; Rice, C.D.; Stuckey, J.; Segars, A.L.; Scott, T.; Talent, L.; Bossart, G.D.; Fair, P.A.; Keller, J.M. Health effects of perfluori-nated compounds- what are the wildlife telling us? Repro. Toxicol. 2009, 27(3-4), 414-415.
42. Qazi, M.R.; Bogdanska, J.; Butenhoff, J.L.; Nelson, B.D.; De-pierre, J.W.; Abedi-Valugerdi, M. (2009). High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or per-fluorooctanoate (PFOA) affects the number of circulating neu-trophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Tox-icol.2007, 262(3), 207-214.
43. Qazi, M.R.; Bogdanska, J.; Butenhoff, J.L.; Nelson, B.D.; DePierre, J.W.; Abedi-Valugerdi, M. Effect of the persistent environmental pollutants perfluorooctane sulfonate (PFOS) and perfluorooc-tanoate (PFOA) on the innate immune system of mice. Society of Toxicology Contemporary Concepts in Toxicology: Perfluoroalkyl Acids and Related Chemistries- Toxicokinetics and Mode of Action Workshop, Arlington, VA, Feb. 14-16, 2007.
44. Houde, M.; Wells, R.S.; Fair, P.A.; Bossart, G.D.; Hohn, A.A.; Rowles, T.K.; Sweeney, J.C.; Solomon, K.R.; Muir, D.C.G. Perflu-oroalkyl compounds in free-ranging bottlenose dolphins (Tursiops truncatus) from the Gulf of Mexico and the Atlantic Ocean. Environ. Sci. Technol. 2005, 39, 6591-6598.
45. Keller, J.M.; Kannan, K.; Taniyasu, S.; Yamashita, N.; Day, R.D.; Arendt, M.D.; Segars, A.L.; Kucklick, J.R. Perfluorinated compounds in the plasma of loggerhead and Kemp's Ridley sea turtles from the Southeastern coast of the United States. Environ. Sci. Technol. 2005, 39(23), 9101-9108.
46. Olsen, G.W.; Burris, J.M.; Burlew, M.M.; Mandel, J.H. Epi-demiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 2003, 45(3), 260-270.
47. Olsen, G.W.; Church, T.R.; Miller, J.P.; Burris, J.M.; Hansen, K.J.; Lundberg, J.K.; Armitage, J.B.; Herron, R.M.; Medhdizadehkashi, Z.; Nobiletti, J.B.; O'Neill, E.M.; Mandel, J.H.; Zobel, L.R. Per-fluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ. Health Perspect. 2003, 111(16), 1892-1901.
48. House, R.V. Theory and practice of cytokine assessment in im-munotoxicology. Methods. 1999, 19(1), 17-27.
49. Hopkins, S.J. Central nervous system recognition of peripheral inflammation: a neural, hormonal collaboration. Acta. Biomed. 2007; 78(Suppl 1), 231-247.
50. Jaattela, M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab. Invest. 1991, 64(6), 724-742.
51. U. S. Environmental Protection Agency (EPA). Health effects test guidelines. Repeated dose 28-day oral toxicity in rodents. OPPTS 870.3505, 1-9, 2000.
52. Luster, M.I.; Portier, C.; Pait, D.G.; White, K.L.; Jr., Gennings, C.; Munson, A.E.; Rosenthal, G.J. Risk assessment in immunotox-icology. I: Sensitivity and predictability of immune tests. Fundam. Appl. Toxicol. 1992, 18, 200-210.
53. Luster, M.I.; Munson, A.E.; Thomas, P.T.; Holsapple, M.P.; Fenters, J.D.; White, K.L.; Jr., Lauer, L.D.; Germolec, D.R.; Rosenthal, G.J.; Dean, J.H. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fundam. Appl. Toxicol. 1988, 10(1), 2-19.
54. Lau, C.; Thibodeaux, J.R.; Hanson, R.G.; Rogers, J.M.; Grey, B.E.; Stanton, M.E., Butenhoff, J.L.; Stevenson, L.A. Exposure to per-fluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol. Sci. 2003, 74(2), 382-392. (Pubitemid 36958307)
55. Olsen, G.W.; Burris, J.M.; Ehresman, D.J.; Froehlich, J.W.; Seacat, A.M.; Butenhoff, J.L.; Zobel, L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perflu-orooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115(9), 1298-1305.
56. Fan, H.; Zingarelli, B.; Harris, V.; Tempel, G.E.; Halushka, P.V.; Cook, J.A. Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways. Mol. Med. 2008, 14(7-8), 422-428.
57. Fan, H.; Williams, D.L.; Zingarelli, B.; Breuel, K.F.; Teti, G.; Tem-pel, G.E.; Spicher, K.; Boulay, G.; Birnbaumer, L.; Halushka, P.V.; Cook, J.A. Differential regulation of lipopolysaccharide and Gram-positive bacteria induced cytokine and chemokine production in splenocytes by Galphai proteins. Biochim. Biophys. Acta 2006, 1763(10), 1051-1058.
58. Fan, H.; Luttrell, L.M.; Tempel, G.E.; Senn, J.J.; Halushka, P.V.; Cook, J.A. Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Mol Immunol. 2007, 44(12), 3092-3099.
59. Hopkins, S.J Central nervous system recognition of peripheral inflammation: a neural, hormonal collaboration. Acta Biomed. 2007, 78(Suppl 1), 231-247.
60. Wollenberg, G.K.; DeForge, L.E.; Bolgos, G.; Remick, D.G. Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am. J. Pathol. 1993, 143, 1121-1130.
61. Lechner, A.J.; Velasquez, A.; Knudsen, K.R.; Johanns, C.A.; Tracy, T.F.; Matuschak, G.M. Cholestatic liver injury increases circulating TNF-α and IL-6 and mortality after Escherichia coli endotoxin. Am. J. Respir. Crit. Care Med. 1998, 157, 1550-1558.
62. Mancuso, G.; Tomasello, F.; Migliardo, M.; Delfino, D.; Cochran, J.; Cook, J.A.; Teti, G. Benefical effects of interleukin-6 in neonatal mouse models of group B Streptococcal disease. Infect. Immun. 1994, 62(11), 4997-5002.
63. Nishimoto, N.; Ito,A.; Ono, M.; Tagoh, H.; Matsumoto, T.; Tomita, T.; Ochi, T.; Yoshizaki, K. IL-6 inhibits the proliferation of fibrob-lastic synivial cells from rheumatiod arthritis patient in the presence of soluble IL-6 receptor. Inter. Immunol. 2000, 12(2), 187-193.
64. Yimin; Kohanawa, M. A regulatory effect of the balance between TNF-α and IL-6 in the granulomatous and inflammatory response to Rhodococus aurantiacus infection in mice. J. Immunol. 2006, 177, 642-650.
65. Copeland, S.; Warren, H.S.; Lowry, S.F.; Calvano, S.E., Remick, D. Acute inflammatory response to endotoxin in mice and humans. Clin. Diag. Lab Immunol. 2005, 12(1), 60-67.
66. Clark, R.B. The role of PPARs in inflammation and immunity. J. Leukoc. Biol. 2002, 71(3), 388-400.
67. Cuzzocrea, S.; Bruscoli, S.; Mazzon, E.; Crisafulli, C.; Donato, V.; Di Paola, R.; Velardi, E.; Esposito, E.; Nocentini, G.; Riccardi, C. Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol. Pharmacol. 2008, 73(2), 323-337.
68. Cuzzocrea, S.; Mazzon, E.; Di Paola, R.; Peli, A.; Bonato, A.; Britti, D.; Genovese, T.; Muia, C.; Crisafulli, C.; Caputi, A.P. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J. Leukoc. Biol. 2006, 79(5), 999-1010. (Pubitemid 44835587)
69. Wolf, C.J.; Takacs, M.L.; Schmid, J.E.; Lau, C.; Abbott, B.D. Activation of mouse and human peroxisome proliferator-activated receptor alpha (PPAR{alpha}) by perfluoroalkyl acids (PFAAs) of different functional groups and chain lengths. Toxicol. Sci. 2008, 106(1), 162-171.
70. Hill, M.R.; Clarke, S.; Rodgers, K.; Thornhill, B.; Peters, J.M.; Gonzalez, F.J.; Gimble, J.M. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect. Immun. 1999, 67(7), 3488-3493.